Impact of Human Immunodeficiency Virus Drug Resistance Mutations Detected in Women Prior to Antiretroviral Therapy With Efavirenz + Tenofovir Disoproxil Fumarate + Lamivudine (or Emtricitabine)
Ceejay L Boyce,Tatiana Sils,Ross S Milne,Jackson J Wallner,Samantha R Hardy,Daisy Ko,Annie Wong-On-Wing,Malia Mackey,Nikki Higa,Ingrid A Beck,Sheila M Styrchak,Patricia DeMarrais,Camlin Tierney,Mary G Fowler,Lisa M Frenkel,Patricia M Flynn,Judith Currier,Susan Fiscus,Katherine Luzuriaga,Adriana Weinberg,James McIntyre,Tsungai Chipato,Lawrence Fox,Karin L Klingman,Renee Browning,Lynne M Mofenson,George K Siberry,Heather Watts,Lynette Purdue,David Shapiro,Terrence Fenton,Mae P Cababasay,Paula Britto,Yan Wang,Li Liu,Sean Brummel,Konstantia Angelidou,Michael Basar,Linda Millar,Kathleen Kaiser,John Gaeddert,Linda Marillo,Andrea Ciaranello,Kenneth Freedberg,Linda Barlow-Mosha,Mary Patricia Toye,Mark Mirochnick,Debika Bhattacharya,Amy Jennings,Adam Manzella,Amanda Zadzilka,William B Kabat,Amy James Loftis,Benjamin Chi,Marc Lallemant,Taha E Taha,Dhayendre Moodley,Karin Nielsen,Arlene Bardeguez,Anna Coutsoudis,Amita Gupta,Risa Hoffman,Elizabeth McFarland,Lynda Stranix-Chibanda,Gerhard B Theron,Lindiwe Msweli,Anne Coletti,Kathleen George,Megan Valentine,Marisol Martinez,James F Rooney,Oxana Ivanova,Danielle Poulin Porter,Wendy Snowden,Helen Watson,Harry Moultrie,Ashraf Coovadia,Renate Strehlau,Gerhard B Theron,Mark Cotton,Magdel Rossouw,Raziya Bobat,Motshidi Sebitloane,Dhayendre Moodley,Avy Violari,Portia Kamthunzi,Mina Hosseinipour,Newton Kumwenda,Mac Mallewa,Pendo Mlay,Anne Buchanan,Namwinga Chintu,Mwangelwa Mubiana-Mbewe,Maxensia Owor,Jim Aizire,Tsungai Chipato,Ramesh Bhosale,Sandhya Khadse,
DOI: https://doi.org/10.1093/ofid/ofae383
2024-06-28
Open Forum Infectious Diseases
Abstract:Abstract Background Two large studies suggest that resistance mutations to only nonnucleoside reverse transcriptase inhibitors (NNRTI) did not increase the risk of virologic failure during antiretroviral therapy (ART) with efavirenz/tenofovir disoproxil fumarate/lamivudine (or emtricitabine). We retrospectively evaluated a third cohort to determine the impact of NNRTI resistance on the efficacy of efavirenz-based ART. Methods Postpartum women living with human immunodeficiency virus (HIV) were studied if they initiated efavirenz-based ART because of the World Health Organization’s recommendation for universal ART. Resistance was detected by Sanger genotyping plasma prior to efavirenz-based ART and at virologic failure (HIV RNA >400 copies/mL). Logistic regression examined relationships between pre-efavirenz genotypes and virologic failure. Results Pre-efavirenz resistance was detected in 169 of 1223 (13.8%) participants. By month 12 of efavirenz-based ART, 189 of 1233 (15.3%) participants had virologic failure. Rates of virologic failure did not differ by pre-efavirenz NNRTI resistance. However, while pre-efavirenz nucleos(t)ide reverse transcriptase inhibitors (NRTI) and NNRTI resistance was rare (8/1223 [0.7%]) this genotype increased the odds (adjusted odds ratio, 11.2 [95% confidence interval, 2.21–72.2]) of virologic failure during efavirenz-based ART. Age, time interval between last viremic visit and efavirenz initiation, clinical site, viremia at delivery, hepatitis B virus coinfection, and antepartum regimen were also associated with virologic failure. Conclusions Resistance to NNRTI alone was prevalent and dual-class (NRTI and NNRTI) resistance was rare in this cohort, with only the latter associated with virologic failure. This confirms others’ findings that, if needed, efavirenz-based ART offers most people an effective alternative to dolutegravir-based ART.
immunology,infectious diseases,microbiology